RC:
Dendritic Cell therapy represents a new and most
promising immunotherapeutic approach to the treatment
of cancer. As Dr. Eyre, VP of Research at the
AMA commented: it is perhaps premature to make
a great deal out of it but, patients' responses
are far out of proportion to anything that any
current therapy could do. DC Therapy is heroretically
sound and has a clinical track record of a 20-30%
response rate even in heavily pretreated advanced
cancers of all types (solid tumors, hematologic
cancers, brain and childhood tumors included).
It is not toxic but requires careful logistic
planning. We have routinely recommended and helped
patients using DC therapy since 2003 in collaboration
with the Institute of Tumortheray in Germany,
and interested patients should visit www.dendritic.info
for more information or otherwise contact
us. |
